Biomind Labs Inc.

Stocks

BMND.F

CA0907021012

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 2026-07-09			5-day change	1st Jan Change
0.0920 ^USD	-16.32%		+729.28%	-19.25%

May. 15	Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Mar. 31	Biomind Labs Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Biomind Labs Inc. Reports Earnings Results for the Full Year Ended December 31, 2024

Published on 08/07/2025 at 04:51 pm EDT

S&P Capital IQ

Add MarketScreener to your sources

BIOMIND LABS INC.

-16.32%

Biomind Labs Inc. reported earnings results for the full year ended December 31, 2024. For the full year, the company reported net loss was USD 0.260479 million compared to USD 1.19 million a year ago.

Add MarketScreener to your sources

Latest news about Biomind Labs Inc.

May. 15	Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Mar. 31	Biomind Labs Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 31	Biomind Labs Inc. Auditor Raises 'Going Concern' Doubt	CI
Jan. 26	Biomind Labs Inc. announced that it expects to receive CAD 2.52 million in funding	CI
Dec. 03	Biomind Labs Inc. Announces Major Strategic Advancement in the Development of BMND08	CI
Nov. 19	Biomind Labs Inc. Appoints Scott Ackerman as an Independent Director of the Board of Directors, and as an Independent Member of the Audit Committee	CI
Nov. 18	Biomind Labs Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-13	Biomind Labs Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-12	Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-08-07	Biomind Labs Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-08-06	Biomind Labs Inc. Auditor Raises 'Going Concern' Doubt	CI
24-10-29	Biomind Labs Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-08-14	Biomind Labs Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-08-02	Biomind Labs Inc. to Redefine Obesity Treatment with Its New BMND06 Candidate Targeting Neurological Pathways	CI
24-07-18	Biomind Labs Inc. Announces the Decision to Advance A New Phase II Clinical Trial	CI

Chart Biomind Labs Inc.

Duration

Period

BMND.F: Dynamic Chart

Company Profile

Biomind Labs Inc. is a biotechnology research and development company. The Company is focused on transforming biomedical sciences knowledge into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, the Company is developing novel pharmaceutical formulations of the main psychedelic molecules, N, N-dimethyltryptamine (DMT), 5- MeO-DMT, and mescaline (collectively, the Molecules), for treating a wide range of therapeutic indications. DMT is a serotonergic psychedelic that exerts its effects through serotonergic receptors in the brain, including 5-HT2A, 5-HT1A, 5-HT2C and 5-HT7 receptors, among others. Under the 5-MeO-DMT Program, it is focused on two drug candidates: the BMND05: 5-MeO-DMT novel formulation indicated for Chronic Pain and the BMND08: 5-MeO-DMT novel formulation indicated for Alzheimerâ€™s disease. Mescaline is a psychedelic alkaloid of the phenethylamine class.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data